• | GAAP ("reported") net sales were $1.15 billion, reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased by approximately 1% excluding the unfavorable impact of currency and exited businesses. |
• | Second quarter reported diluted earnings per share ("EPS") was $0.07; adjusted diluted EPS was $0.86 per share. |
• | Perrigo Worldwide Consumer reported net sales were $910 million for the second quarter, down 5% year-over-year. Excluding exited businesses and the unfavorable impact of currency, Worldwide Consumer net sales were flat year-over-year. |
• | Consumer Self-Care Americas OTC Store Brands grew their leadership positions, gaining market share in nearly every category. |
• | Consumer Self-Care International business maintained market share in robust European market that is growing low-to-mid single digits. |
• | Prescription Pharmaceuticals net sales of $239 million were 3% higher year-over-year, driven by strong new product launches and continued moderation of pricing pressure. |
• | Reaffirms Adjusted EPS Guidance - the Company expects 2019 reported diluted EPS to be in the range of $1.23 to $1.53 and reaffirms 2019 adjusted diluted EPS to be in the range of to $3.75 to $4.05. Guidance includes the Ranir acquisition and Animal Health divestiture, which both closed in July as part of the Company's portfolio reconfiguration to consumer self-care. |
Second Quarter Ended | Second Quarter Ended | YoY | Constant Currency | |||||||
6/29/2019 | 6/30/2018 | % Change | % Change | |||||||
Reported Net Sales | $1,149 | $1,186 | (3.1 | )% | (1.1 | )% | ||||
Reported Net Income | $9 | $36 | (75.1 | )% | ||||||
Reported Diluted Earnings per Share | $0.07 | $0.26 | (74.7 | )% | ||||||
Reported Diluted Shares | 136.5 | 138.7 | (1.5 | )% | ||||||
Adjusted Net Sales | $1,127 | NA | NA | |||||||
Adjusted Net Income | $117 | $169 | (30.5 | )% | ||||||
Adjusted Diluted Earnings per Share | $0.86 | $1.22 | (29.4 | )% |
Second Quarter Ended | Second Quarter Ended | YoY | Constant Currency | ||||||||
6/29/2019 | 6/30/2018 | % Change | % Change | ||||||||
Reported Net Sales | $582 | $597 | (2.5 | )% | (2.5 | )% | |||||
Reported Gross Profit | $197 | $203 | (2.8 | )% | |||||||
Reported Gross Margin | 33.8 | % | 33.9 | % | (10) bps | ||||||
Reported Operating Income | $108 | $65 | 66.8 | % | |||||||
Reported Operating Margin | 18.5 | % | 10.8 | % | 770 bps | ||||||
Adjusted Net Sales | $560 | NA | NA | ||||||||
Adjusted Gross Profit | $190 | $213 | (10.7 | )% | |||||||
Adjusted Gross Margin | 34.0 | % | 35.7 | % | (170) bps | ||||||
Adjusted Operating Income | $114 | $129 | (11.9 | )% | |||||||
Adjusted Operating Margin | 20.3 | % | 21.6 | % | (130) bps |
Second Quarter Ended | Second Quarter Ended | YoY | Constant Currency | ||||||||
6/29/2019 | 6/30/2018 | % Change | % Change | ||||||||
Reported Net Sales | $328 | $358 | (8.5 | )% | (1.8 | )% | |||||
Reported Gross Profit | $155 | $173 | (10.3 | )% | |||||||
Reported Gross Margin | 47.4 | % | 48.4 | % | (100) bps | ||||||
Reported Operating income (loss) | $(3) | $4 | (173.5 | )% | |||||||
Reported Operating Margin | (0.9 | )% | 1.1 | % | (200) bps | ||||||
Adjusted Gross Profit | $175 | $195 | (10.1 | )% | |||||||
Adjusted Gross Margin | 53.5 | % | 54.5 | % | (100) bps | ||||||
Adjusted Operating Income | $50 | $56 | (10.6 | )% | |||||||
Adjusted Operating Margin | 15.3 | % | 15.6 | % | (30) bps |
Second Quarter Ended | Second Quarter Ended | YoY | Constant Currency | ||||||||
6/29/2019 | 6/30/2018 | % Change | % Change | ||||||||
Reported Net Sales | $239 | $232 | 3.4 | % | 3.4 | % | |||||
Reported Gross Profit | $79 | $95 | (17.5 | )% | |||||||
Reported Gross Margin | 32.8 | % | 41.1 | % | (830) bps | ||||||
Reported Operating Income | $15 | $54 | (72.6 | )% | |||||||
Reported Operating Margin | 6.1 | % | 23.1 | % | (1,700) bps | ||||||
Adjusted Gross Profit | $100 | $116 | (13.8 | )% | |||||||
Adjusted Gross Margin | 41.7 | % | 50.0 | % | (830) bps | ||||||
Adjusted Operating Income | $66 | $79 | (17.2 | )% | |||||||
Adjusted Operating Margin | 27.4 | % | 34.1 | % | (670) bps |
• | The Company reaffirms its adjusted diluted EPS to be in the range of to $3.75 to $4.05 per share. Guidance includes the Ranir acquisition and Animal Health divestiture. |
• | Potential upside to this adjusted EPS range includes contributions from a launch of the generic version of ProAir® (+ $0.00 – $0.10 cents) and/or incremental cost savings from Project Momentum of up to $0.05. |
• | The Company expects an acceleration of net sales growth in the second half of the year driven by Ranir (excluding animal health, exited infant foods and impact of currency). |
Three Months Ended | Six Months Ended | ||||||||||||||
June 29, 2019 | June 30, 2018 | June 29, 2019 | June 30, 2018 | ||||||||||||
Net sales | $ | 1,149.0 | $ | 1,186.4 | $ | 2,323.5 | $ | 2,403.4 | |||||||
Cost of sales | 718.2 | 715.4 | 1,443.9 | 1,439.7 | |||||||||||
Gross profit | 430.8 | 471.0 | 879.6 | 963.7 | |||||||||||
Operating expenses | |||||||||||||||
Distribution | 23.7 | 23.8 | 47.1 | 48.5 | |||||||||||
Research and development | 43.9 | 91.9 | 84.0 | 130.3 | |||||||||||
Selling | 140.1 | 155.2 | 288.7 | 316.5 | |||||||||||
Administration | 127.2 | 96.8 | 252.3 | 204.5 | |||||||||||
Impairment charges | 27.8 | 1.7 | 31.9 | 1.7 | |||||||||||
Restructuring | 12.2 | 3.7 | 21.5 | 5.2 | |||||||||||
Other operating expense (income) | 0.9 | 3.2 | (3.2 | ) | 6.1 | ||||||||||
Total operating expenses | 375.8 | 376.3 | 722.3 | 712.8 | |||||||||||
Operating income | 55.0 | 94.7 | 157.3 | 250.9 | |||||||||||
Change in financial assets | (5.5 | ) | (0.6 | ) | (15.9 | ) | 9.0 | ||||||||
Interest expense, net | 31.2 | 32.1 | 59.8 | 63.5 | |||||||||||
Other (income) expense, net | 2.3 | 7.9 | 5.5 | 12.1 | |||||||||||
Loss on extinguishment of debt | — | — | — | 0.5 | |||||||||||
Income before income taxes | 27.0 | 55.3 | 107.9 | 165.8 | |||||||||||
Income tax expense | 18.0 | 19.1 | 35.0 | 48.8 | |||||||||||
Net income | $ | 9.0 | $ | 36.2 | $ | 72.9 | $ | 117.0 | |||||||
Earnings per share | |||||||||||||||
Basic | $ | 0.07 | $ | 0.26 | $ | 0.54 | $ | 0.84 | |||||||
Diluted | $ | 0.07 | $ | 0.26 | $ | 0.54 | $ | 0.84 | |||||||
Weighted-average shares outstanding | |||||||||||||||
Basic | 136.0 | 138.1 | 136.0 | 139.5 | |||||||||||
Diluted | 136.5 | 138.7 | 136.3 | 140.0 |
June 29, 2019 | December 31, 2018 | ||||||
Assets | |||||||
Cash and cash equivalents | $ | 1,055.7 | $ | 551.1 | |||
Accounts receivable, net of allowance for doubtful accounts of $6.3 and $6.4, respectively | 1,117.1 | 1,073.1 | |||||
Inventories | 940.5 | 878.0 | |||||
Prepaid expenses and other current assets | 322.1 | 400.0 | |||||
Total current assets | 3,435.4 | 2,902.2 | |||||
Property, plant and equipment, net | 824.3 | 829.1 | |||||
Operating lease assets | 135.4 | — | |||||
Goodwill and indefinite-lived intangible assets | 3,967.8 | 4,029.1 | |||||
Definite-lived intangible assets, net | 2,675.2 | 2,858.9 | |||||
Deferred income taxes | 6.8 | 1.2 | |||||
Other non-current assets | 383.8 | 362.9 | |||||
Total non-current assets | 7,993.3 | 8,081.2 | |||||
Total assets | $ | 11,428.7 | $ | 10,983.4 | |||
Liabilities and Shareholders’ Equity | |||||||
Accounts payable | $ | 513.7 | $ | 474.9 | |||
Payroll and related taxes | 126.3 | 132.1 | |||||
Accrued customer programs | 385.2 | 442.4 | |||||
Accrued liabilities | 262.7 | 201.3 | |||||
Accrued income taxes | 104.1 | 96.5 | |||||
Current indebtedness | 398.8 | 190.2 | |||||
Total current liabilities | 1,790.8 | 1,537.4 | |||||
Long-term debt, less current portion | 3,084.4 | 3,052.2 | |||||
Deferred income taxes | 280.2 | 282.3 | |||||
Other non-current liabilities | 546.9 | 443.4 | |||||
Total non-current liabilities | 3,911.5 | 3,777.9 | |||||
Total liabilities | 5,702.3 | 5,315.3 | |||||
Commitments and contingencies - Refer to Note 15 | |||||||
Shareholders’ equity | |||||||
Controlling interests: | |||||||
Preferred shares, $0.0001 par value per share, 10 shares authorized | — | — | |||||
Ordinary shares, €0.001 par value per share, 10,000 shares authorized | 7,395.5 | 7,421.7 | |||||
Accumulated other comprehensive income | 99.5 | 84.6 | |||||
Retained earnings (accumulated deficit) | (1,768.8 | ) | (1,838.3 | ) | |||
Total controlling interest | 5,726.2 | 5,668.0 | |||||
Noncontrolling interest | 0.2 | 0.1 | |||||
Total shareholders’ equity | 5,726.4 | 5,668.1 | |||||
Total liabilities and shareholders' equity | $ | 11,428.7 | $ | 10,983.4 | |||
Supplemental Disclosures of Balance Sheet Information | |||||||
Preferred shares, issued and outstanding | — | — | |||||
Ordinary shares, issued and outstanding | 136.0 | 135.9 |
Six Months Ended | |||||||
June 29, 2019 | June 30, 2018 | ||||||
Cash Flows From (For) Operating Activities | |||||||
Net income | $ | 72.9 | $ | 117.0 | |||
Adjustments to derive cash flows: | |||||||
Depreciation and amortization | 191.5 | 217.8 | |||||
Share-based compensation | 28.0 | 22.3 | |||||
Impairment charges | 31.9 | 1.7 | |||||
Change in financial assets | (15.9 | ) | 9.0 | ||||
Loss on extinguishment of debt | — | 0.5 | |||||
Restructuring charges | 21.5 | 5.2 | |||||
Deferred income taxes | 9.2 | (14.2 | ) | ||||
Amortization of debt premium | (3.0 | ) | (3.7 | ) | |||
Other non-cash adjustments, net | 26.4 | 5.1 | |||||
Subtotal | 362.5 | 360.7 | |||||
Increase (decrease) in cash due to: | |||||||
Accounts receivable | (55.3 | ) | (24.3 | ) | |||
Inventories | (78.3 | ) | (99.3 | ) | |||
Accounts payable | 41.2 | 89.2 | |||||
Payroll and related taxes | (23.0 | ) | (48.4 | ) | |||
Accrued customer programs | (52.8 | ) | 33.9 | ||||
Accrued liabilities | (19.2 | ) | (30.4 | ) | |||
Accrued income taxes | (36.7 | ) | (20.8 | ) | |||
Other, net | 19.9 | (5.9 | ) | ||||
Subtotal | (204.2 | ) | (106.0 | ) | |||
Net cash from (for) operating activities | 158.3 | 254.7 | |||||
Cash Flows From (For) Investing Activities | |||||||
Proceeds from royalty rights | 1.7 | 10.3 | |||||
Purchase of investment securities | — | (7.5 | ) | ||||
Royalty Pharma contingent milestone payment | 250.0 | — | |||||
Asset acquisitions | (35.0 | ) | — | ||||
Additions to property, plant and equipment | (54.7 | ) | (33.3 | ) | |||
Net proceeds from sale of business and other assets | — | 1.3 | |||||
Net cash from (for) investing activities | 162.0 | (29.2 | ) | ||||
Cash Flows From (For) Financing Activities | |||||||
Issuances of long-term debt | — | 431.0 | |||||
Payments on long-term debt | (158.9 | ) | (457.3 | ) | |||
Borrowings (repayments) of revolving credit agreements and other financing, net | 397.5 | (8.2 | ) | ||||
Deferred financing fees | — | (2.4 | ) | ||||
Issuance of ordinary shares | 0.3 | — | |||||
Repurchase of ordinary shares | — | (265.0 | ) | ||||
Cash dividends | (54.8 | ) | (52.8 | ) | |||
Other financing, net | (5.9 | ) | (7.5 | ) | |||
Net cash from (for) financing activities | 178.2 | (362.2 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents | 6.1 | (15.5 | ) | ||||
Net increase (decrease) in cash and cash equivalents | 504.6 | (152.2 | ) | ||||
Cash and cash equivalents, beginning of period | 551.1 | 678.7 | |||||
Cash and cash equivalents, end of period | $ | 1,055.7 | $ | 526.5 |
TABLE I | |||||||||
PERRIGO COMPANY PLC | |||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||
SELECTED CONSOLIDATED INFORMATION | |||||||||
(in millions, except per share amounts) | |||||||||
(unaudited) | |||||||||
Three Months Ended June 29, 2019 | |||||||||
Consolidated | Net Sales | Net Income | Diluted Earnings per Share | ||||||
Reported | $ | 1,149.0 | $ | 9.0 | $ | 0.07 | |||
Adjustments: | |||||||||
Amortization expense related primarily to acquired intangible assets | $ | — | $ | 74.4 | $ | 0.56 | |||
Impairment charges | — | 27.8 | 0.20 | ||||||
Restructuring charges and other termination benefits | — | 12.2 | 0.09 | ||||||
Unusual litigation | — | 7.0 | 0.05 | ||||||
Separation and reorganization expense | — | 7.5 | 0.05 | ||||||
Acquisition and integration-related charges and contingent consideration adjustments | — | 3.1 | 0.02 | ||||||
Gain/loss on divestitures | — | 0.8 | 0.01 | ||||||
Loss on investment securities | — | 1.8 | 0.01 | ||||||
Operating results attributable to held-for-sale business* | (22.3 | ) | (3.5 | ) | (0.03 | ) | |||
Change in financial assets | — | (5.5 | ) | (0.04 | ) | ||||
Non-GAAP tax adjustments** | — | (17.2 | ) | (0.13 | ) | ||||
Adjusted | $ | 1,126.7 | $ | 117.4 | $ | 0.86 | |||
Diluted weighted average shares outstanding | |||||||||
Reported | 136.5 | ||||||||
*Held-for-sale business includes the animal health business. | |||||||||
**The non-GAAP tax adjustments are due to tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax items. |
TABLE I (CONTINUED) | |||||||||
PERRIGO COMPANY PLC | |||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||
SELECTED CONSOLIDATED INFORMATION | |||||||||
(in millions, except per share amounts) | |||||||||
(unaudited) | |||||||||
Three Months Ended June 30, 2018 | |||||||||
Consolidated | Net Sales | Net Income | Diluted Earnings per Share | ||||||
Reported | $ | 1,186.4 | $ | 36.2 | $ | 0.26 | |||
Adjustments: | |||||||||
Amortization expense primarily related to acquired intangible assets | $ | 86.5 | $ | 0.62 | |||||
Acquisition and integration-related charges and contingent consideration adjustments | 53.2 | 0.38 | |||||||
Loss on investment securities | 6.3 | 0.05 | |||||||
Restructuring charges and other termination benefits | 3.7 | 0.03 | |||||||
Impairment charges | 1.7 | 0.01 | |||||||
Change in financial assets | (0.6 | ) | — | ||||||
Non-GAAP tax adjustments* | (18.1 | ) | (0.13 | ) | |||||
Adjusted | $ | 168.9 | $ | 1.22 | |||||
Diluted weighted average shares outstanding | |||||||||
Reported | 138.7 | ||||||||
2018 QTD Net Sales excluding the animal health business** | |||||||||
Reported | $ | 1,186.4 | |||||||
Operating results attributable to held-for-sale business*** | (31.9 | ) | |||||||
Adjusted | $ | 1,154.5 | |||||||
*The non-GAAP tax adjustments are due primarily to tax effects of pretax non-GAAP adjustments that are calculated based upon the specific rate of the applicable jurisdiction of the pretax items. | |||||||||
**For comparative purposes only. | |||||||||
***Held-for-sale business includes the animal health business. |
TABLE II | |||||||||||||||||||||||||||||||
PERRIGO COMPANY PLC | |||||||||||||||||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||||||||||||||||||||||||
SELECTED SEGMENT INFORMATION | |||||||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||||||
Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||||
June 29, 2019 | June 30, 2018 | ||||||||||||||||||||||||||||||
Consumer Self-Care Americas | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | |||||||||||||||||||||
Reported | $ | 582.1 | $ | 196.8 | $ | 18.8 | $ | 70.2 | $ | 107.8 | $ | 596.9 | $ | 202.5 | $ | 66.4 | $ | 72.4 | $ | 64.6 | |||||||||||
As a % of reported net sales | 33.8 | % | 3.2 | % | 12.1 | % | 18.5 | % | 33.9 | % | 11.1 | % | 12.1 | % | 10.8 | % | |||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Amortization expense related primarily to acquired intangible assets | $ | — | $ | 4.7 | $ | — | $ | (4.5 | ) | $ | 9.2 | $ | 10.6 | $ | — | $ | (4.8 | ) | $ | 15.3 | |||||||||||
Unusual litigation | — | — | — | (0.2 | ) | 0.2 | — | — | — | — | |||||||||||||||||||||
Impairment charges | — | — | — | — | — | — | — | — | 0.6 | ||||||||||||||||||||||
Operating results attributable to held-for-sale business* | (22.3 | ) | (11.2 | ) | (0.4 | ) | (7.3 | ) | (3.5 | ) | — | — | — | — | |||||||||||||||||
Acquisition and integration-related charges and contingent consideration adjustments | — | — | — | — | — | — | (50.0 | ) | — | 48.5 | |||||||||||||||||||||
Adjusted | $ | 559.8 | $ | 190.3 | $ | 18.4 | $ | 58.2 | $ | 113.7 | $ | 213.1 | $ | 16.4 | $ | 67.6 | $ | 129.0 | |||||||||||||
As a % of adjusted net sales (2019) / As a % of reported net sales (2018) | 34.0 | % | 3.3 | % | 10.4 | % | 20.3 | % | 35.7 | % | 2.7 | % | 11.3 | % | 21.6 | % | |||||||||||||||
2018 QTD Net Sales excluding the animal health business** | |||||||||||||||||||||||||||||||
Reported | $ | 596.9 | |||||||||||||||||||||||||||||
Operating results attributable to held-for-sale business* | (31.9 | ) | |||||||||||||||||||||||||||||
Adjusted | $ | 565.0 | |||||||||||||||||||||||||||||
*Held-for-sale business includes the animal health business. | |||||||||||||||||||||||||||||||
**For comparative purposes only. |
Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||||
June 29, 2019 | June 30, 2018 | ||||||||||||||||||||||||||||||
Consumer Self-Care International | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income (Loss) | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | |||||||||||||||||||||
Reported | $ | 327.5 | $ | 155.4 | $ | 11.2 | $ | 138.0 | $ | (2.9 | ) | $ | 357.9 | $ | 173.2 | $ | 11.2 | $ | 156.5 | $ | 4.0 | ||||||||||
As a % of reported net sales | 47.4 | % | 3.4 | % | 42.1 | % | (0.9 | )% | 48.4 | % | 3.1 | % | 43.7 | % | 1.1 | % | |||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Amortization expense related primarily to acquired intangible assets | $ | 19.9 | $ | (0.1 | ) | $ | (23.8 | ) | $ | 43.8 | $ | 21.8 | $ | (0.3 | ) | $ | (28.4 | ) | $ | 50.4 | |||||||||||
Impairment charges | — | — | — | — | — | — | — | 1.0 | |||||||||||||||||||||||
Restructuring charges and other termination benefits | — | — | — | 9.1 | — | — | — | 0.5 | |||||||||||||||||||||||
Adjusted | $ | 175.3 | $ | 11.1 | $ | 114.2 | $ | 50.0 | $ | 195.0 | $ | 10.9 | $ | 128.1 | $ | 55.9 | |||||||||||||||
As a % of reported net sales | 53.5 | % | 3.4 | % | 34.9 | % | 15.3 | % | 54.5 | % | 3.0 | % | 35.8 | % | 15.6 | % |
TABLE II (CONTINUED) | |||||||||||||||||||||||||||||||
PERRIGO COMPANY PLC | |||||||||||||||||||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||||||||||||||||||||||||
SELECTED SEGMENT INFORMATION | |||||||||||||||||||||||||||||||
(in millions) | |||||||||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||||||||
Three Months Ended | Three Months Ended | ||||||||||||||||||||||||||||||
June 29, 2019 | June 30, 2018 | ||||||||||||||||||||||||||||||
Prescription Pharmaceuticals | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | |||||||||||||||||||||
Reported | $ | 239.4 | $ | 78.6 | $ | 13.8 | $ | 21.4 | $ | 14.7 | $ | 231.6 | $ | 95.3 | $ | 14.4 | $ | 22.6 | $ | 53.6 | |||||||||||
As a % of reported net sales | 32.8 | % | 5.8 | % | 8.9 | % | 6.1 | % | 41.1 | % | 6.2 | % | 9.8 | % | 23.1 | % | |||||||||||||||
Adjustments: | |||||||||||||||||||||||||||||||
Amortization expense related primarily to acquired intangible assets | $ | 21.2 | $ | (0.1 | ) | $ | 21.3 | $ | 20.6 | $ | (0.2 | ) | $ | 20.8 | |||||||||||||||||
Separation and reorganization expense | — | (0.8 | ) | 0.8 | — | — | — | ||||||||||||||||||||||||
Impairment charges | — | — | 27.8 | — | — | — | |||||||||||||||||||||||||
Acquisition and integration-related charges and contingent consideration adjustments | — | — | 0.9 | — | — | 4.7 | |||||||||||||||||||||||||
Adjusted | $ | 99.8 | $ | 20.5 | $ | 65.5 | $ | 115.9 | $ | 22.4 | $ | 79.1 | |||||||||||||||||||
As a % of reported net sales | 41.7 | % | 8.6 | % | 27.4 | % | 50.0 | % | 9.7 | % | 34.1 | % |
TABLE II (CONTINUED) | |||||||||||||||
PERRIGO COMPANY PLC | |||||||||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||||||||
SELECTED SEGMENT INFORMATION | |||||||||||||||
(in millions) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended | |||||||||||||||
March 30, 2019 | |||||||||||||||
Consumer Self-Care Americas | Net Sales | Gross Profit | R&D Expense | DSG&A Expense | Operating Income | ||||||||||
Reported | $ | 581.8 | $ | 184.0 | $ | 15.6 | $ | 73.3 | $ | 94.2 | |||||
As a % of reported net sales | 31.6 | % | 2.7 | % | 12.6 | % | 16.2 | % | |||||||
Adjustments: | |||||||||||||||
Amortization expense related primarily to acquired intangible assets | $ | 5.4 | $ | (4.7 | ) | $ | 10.1 | ||||||||
Unusual litigation | — | (1.2 | ) | 1.2 | |||||||||||
Impairment charges | — | — | 4.1 | ||||||||||||
Restructuring charges and other termination benefits | — | — | 0.8 | ||||||||||||
Acquisition and integration-related charges and contingent consideration adjustments | — | — | (4.1 | ) | |||||||||||
Adjusted | $ | 189.4 | $ | 67.4 | $ | 106.3 | |||||||||
As a % of reported net sales | 32.5 | % | 11.6 | % | 18.3 | % | |||||||||
TABLE III | |||||||||||||
PERRIGO COMPANY PLC | |||||||||||||
RECONCILIATION OF NON-GAAP MEASURES | |||||||||||||
CONSTANT CURRENCY | |||||||||||||
(in millions) | |||||||||||||
(unaudited) | |||||||||||||
Three Months Ended | |||||||||||||
June 29, 2019 | June 30, 2018 | Total Change | FX Change | Constant Currency Change | |||||||||
Net sales | |||||||||||||
Consolidated | $ | 1,149.0 | $ | 1,186.4 | (3.1)% | 2.0% | (1.1)% | ||||||
CSCA | $ | 582.1 | $ | 596.9 | (2.5)% | —% | (2.5)% | ||||||
CSCI | $ | 327.5 | $ | 357.9 | (8.5)% | 6.7% | (1.8)% | ||||||
RX | $ | 239.4 | $ | 231.6 | 3.4% | —% | 3.4% | ||||||
Consolidated | $ | 1,149.0 | $ | 1,186.4 | |||||||||
Less: animal health | (22.3 | ) | (31.9 | ) | |||||||||
Less: infant foods | (0.8 | ) | (10.0 | ) | |||||||||
$ | 1,125.9 | $ | 1,144.5 | (1.6)% | 2.1% | 0.5% | |||||||
CSCA | $ | 582.1 | $ | 596.9 | |||||||||
Less: animal health | (22.3 | ) | (31.9 | ) | |||||||||
Less: infant foods | (0.8 | ) | (10.0 | ) | |||||||||
$ | 559.0 | $ | 555.0 | 0.7% | 0.1% | 0.8% | |||||||
Worldwide Consumer | |||||||||||||
CSCA | $ | 582.1 | $ | 596.9 | |||||||||
CSCI | 327.5 | 357.9 | |||||||||||
$ | 909.6 | $ | 954.8 | (4.7)% | 2.4% | (2.3)% | |||||||
Less: animal health | (22.3 | ) | (31.9 | ) | |||||||||
Less: infant foods | (0.8 | ) | (10.0 | ) | |||||||||
$ | 886.5 | $ | 912.9 | (2.9)% | 2.7% | (0.2)% | |||||||
TABLE IV | |
PERRIGO COMPANY PLC | |
RECONCILIATION OF NON-GAAP MEASURES | |
2019 CONSOLIDATED GUIDANCE(1) | |
(in millions) | |
(unaudited) | |
Full Year | |
2019 EPS Guidance | |
Reported(2) | $1.23 - $1.53 |
Amortization expense related primarily to acquired intangible assets | 2.20 |
Impairment charges | 0.23 |
Unusual litigation | 0.20 |
Restructuring charges and other termination benefits | 0.16 |
Separation and reorganization expense | 0.13 |
Acquisition-related charges and contingent consideration adjustments | 0.09 |
Losses on investment securities | 0.06 |
Change in financial assets | (0.12) |
Operating results attributable to held-for-sale business* | (0.03) |
Tax effect of non-GAAP adjustments | (0.40) |
Adjusted | $3.75 - $4.05 |
(1) Guidance table includes Q1 and Q2 actual results for all reconciling line items, plus estimated amortization expense, separation and reorganization expense, unusual litigation, acquisition-related charges and the corresponding tax effect for Q3-Q4. | |
(2) Guidance excludes Q2-Q4 impact related to the Royalty Pharma contingent milestone payments. |
TABLE V (continued) | ||||||||||
PERRIGO COMPANY PLC | ||||||||||
RECONCILIATION OF NON-GAAP MEASURES | ||||||||||
SELECTED CONSOLIDATED AND SEGMENT INFORMATION | ||||||||||
(in millions, except per share amounts) | ||||||||||
(unaudited) | ||||||||||
Three Months Ended | ||||||||||
June 29, 2019 | June 30, 2018 | Total Change | ||||||||
Consolidated adjusted net sales | $ | 1,126.7 | NA | (5.0)% | ||||||
Consolidated adjusted net income | $ | 117.4 | $ | 168.9 | (30.5)% | |||||
Consolidated adjusted EPS | $ | 0.86 | $ | 1.22 | (29.4)% | |||||
Adjusted net sales | ||||||||||
CSCA | $ | 559.8 | NA | (6.2)% | ||||||
Adjusted gross profit | ||||||||||
CSCA | $ | 190.3 | $ | 213.1 | (10.7)% | |||||
CSCI | $ | 175.3 | $ | 195.0 | (10.1)% | |||||
RX | $ | 99.8 | $ | 115.9 | (13.8)% | |||||
Adjusted gross margin | ||||||||||
CSCA | 34.0 | % | 35.7 | % | (170) bps | |||||
CSCI | 53.5 | % | 54.5 | % | (100) bps | |||||
RX | 41.7 | % | 50.0 | % | (830) bps | |||||
Adjusted operating income | ||||||||||
CSCA | $ | 113.7 | $ | 129.0 | (11.9)% | |||||
CSCI | $ | 50.0 | $ | 55.9 | (10.6)% | |||||
RX | $ | 65.5 | $ | 79.1 | (17.2)% | |||||
Adjusted operating margin | ||||||||||
CSCA | 20.3 | % | 21.6 | % | (130) bps | |||||
CSCI | 15.3 | % | 15.6 | % | (30) bps | |||||
RX | 27.4 | % | 34.1 | % | (670) bps | |||||